A Phase 2/3 interventional study of AT-007 and Placebo in Classic Galactosemia, sponsored by Applied Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by Applied Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).
This is a randomized, double-blind, placebo-controlled study in pediatric subjects with CG. Children with CG ages 2 through 17 years will be enrolled. The study is designed to assess the clinical benefit using validated, standardized Clinical Outcome Assessments (COAs) as well as the safety, PK, and PD (reduction of galactitol levels) of AT-007 in pediatric subjects with CG. The study consists of 2 main parts, Part A and Part B, and an open-label extension (OLE).
Part A is an intra-patient dose escalation evaluating multiple ascending doses (MAD) of AT-007.
Part B is designed to assess the clinical benefits of long-term administration of AT-007 (at the optimum dose identified in Part A) on validated, standardized COAs.
Open-label extension (OLE) is an active treatment extension for patients who received placebo treatment in Part B.
Applied Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
AT-007 The starting dose in Part A will be 5 mg/kg for all age groups. For each age group, Part B of the study will not start until the optimum dose evaluated in Part A has been identified
Drug: AT-007
Placebo given orally
Other: Placebo
Treatment with AT-007 given orally
Also known as: aldose reductase inhibitor
Placebo given orally
Global Statistical Test (GST)
The primary endpoint is a GST of four components: 1) Behavioral Symptoms Index of the Behavioral Assessment Scale for Children 3 (BASC-3); 2) Activities of Daily Living from the BASC-3; 3) Oral Expression from the Oral and Written Language Skills-II (OWLS-II); 4) Listening Comprehension from the OWLS-II. Each individual component is also a secondary endpoint on their own with the test and scoring described below in the secondary endpoint section. For the GST, change from baseline using standardized z-scores is calculated for active versus placebo.
Time frame: Month 6, Month 12 and Month 18
Sensitivity Analysis of the Primary Endpoint (GST) with Cognition
Sensitivity Analysis adding the National Institutes of Health Toolbox Cognition Battery (NIH-CB) test which measures cognition. NIH-CB is described below in the secondary endpoints. For the GST with cognition, change from baseline using standardized z-scores is calculated for active versus placebo.
Time frame: Month 6, Month 12 and Month 18
Sensitivity Analysis of the Primary Endpoint (GST) with Fine Motor Skills
Sensitivity Analysis adding the National Institutes of Health Toolbox Motor Battery (NIH-MB) 9-Hole Pegboard test which measures fine motor skills. NIH-MB is described below in the secondary endpoints. For the GST with fine motor skills, change from baseline using standardized z-scores is calculated for active versus placebo.
Time frame: Month 6, Month 12 and Month 18
Galactitol Level
The change from baseline in plasma galactitol (Pharmacodynamic measure)
Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18
Behavioral Assessment System for Children-3 [Individual Components]
Behavioral Assessment System for Children (BASC-3) has a normal range of 40-60 with the higher score showing more difficulty. There are multiple outcome scores included such as: Behavioral Symptoms Index, Activities of Daily Living, Withdrawal, Adapatability, Adaptive Skills, Socialization, and Functional Impairment Index.
Time frame: Month 6, Month 12 and Month 18
National Institute of Health Toolbox Cognition Battery
Change from baseline in the NIH Toolbox Cognition Battery (NIH-CB). The NIH-CB uses multiple tests to evaluate Cognition and consists of tests of multiple constructs to yield individual ranking and demonstrate Cognitive Function Composite, Fluid Cognition Composite Sequence Memory, List Sorting, Pattern Comparison, and Crystallized Cognition Composite, Picture Vocabulary and Reading Recognition. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.
Time frame: Month 6, Month 12 and Month 18
Archimedes Spiral Drawing Test
The Archimedes Spiral Drawing Test evaluates tremor on a scale of 0 (no tremor) to 4 (severe tremor).
Time frame: Month 6, Month 12 and Month 18
National Institute of Health Toolbox Motor Battery
NIH Toolbox Motor Battery (NIH-MB) is a multiple of tests to determine fine motor skills using the 9-Hole Pegboard Test and gross motor skills using the Standing Balance Test. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.
Time frame: Month 6, Month 12 and Month 18
Scale for Assessment & Rating of Ataxia
Scale for Assessment \& Rating of Ataxia (SARA) is 0-40, the higher the score the worse value
Time frame: Month 6, Month 12 and Month 18
Oral and Written Language Scales-II
Oral and Written Language Scales-II (OWLS-II) has both an Oral Expression and Listening Comprehension score. Scores are 0-100 with a standard deviation of 15.
Time frame: Month 6, Month 12 and Month 18
Rate of Lens Opacity
Onset and severity/progression of cataracts using the Lens Opacity System (LOCS) III, has a grading scale of 1-4, with 4 the most severe as assessed by the reviewer per standard criteria for anterior and posterior obstruction of the eye.
Time frame: Month 6, Month 12 and Month 18
Sexual maturation in female patients as indicated by Tanner Stage
Sexual maturation in female patients as indicated by Tanner Stage 1- 4 which is the ranking of physical development in children, adolescents and adults. This defines physical measurements of development based on external primary and secondary sex characteristics, such as the size of the breasts, and development of pubic hair. This is assessed by physical exam with Stage 1 per-pubescent and Stage 4 post pubescent.
Time frame: Month 6, Month 12 and Month 18
Ovarian function in female patients determined by hormonal tests.
Ovarian function in female patients is recorded by hormonal measures: FSH (follicle stimulating hormone), estradiol, and LH (luteinizing hormone).
Time frame: Month 6, Month 12 and Month 18
Biomarker Analysis [Exploratory]
This biomarker analysis will be performed to assess the levels of galactose and its other metabolites; Exploratory Endpoint
Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18
Bayley Scales of Infant and Toddler Development-4 [Exploratory]
Bayley Scales of Infant and Toddler Development (Bayley-4) showing a score of 40 -160 with higher values showing more development. Exploratory Endpoint
Time frame: Month 6, Month 12 and Month 18
Vineland Adaptive Behavior Scales-3 [Exploratory]
Vineland Adaptive Behavior Scales (Vineland-3) has a normal score of 100 and lower scores show developmental delay; Exploratory Endpoint
Time frame: Month 6, Month 12 and Month 18
Plan to share: No
Ran from Mar 2021 to primary completion in Mar 2023, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Govorestat
Galactosemias
Applied Therapeutics, Inc.